aquestive therapeutics inc. - AQST
AQST
Close Chg Chg %
3.67 -0.09 -2.45%
Closed Market
3.58
-0.09 (2.45%)
Volume: 893.20K
Last Updated:
Jan 3, 2025, 4:00 PM EDT
Company Overview: aquestive therapeutics inc. - AQST
AQST Key Data
| Open $3.69 | Day Range 3.57 - 3.77 |
| 52 Week Range 2.07 - 6.23 | Market Cap $334.62M |
| Shares Outstanding 91.18M | Public Float 77.61M |
| Beta 2.71 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.45 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.49M |
AQST Performance
| 1 Week | 1.70% | ||
| 1 Month | -14.15% | ||
| 3 Months | -27.68% | ||
| 1 Year | 52.99% | ||
| 5 Years | -38.91% |
AQST Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About aquestive therapeutics inc. - AQST
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
AQST At a Glance
Aquestive Therapeutics, Inc.
30 Technology Drive
Warren, New Jersey 07059
| Phone | 1-908-941-1900 | Revenue | 50.58M | |
| Industry | Pharmaceuticals: Major | Net Income | -7,870,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 6.089% | |
| Fiscal Year-end | 12 / 2024 | Employees | 135 | |
| View SEC Filings |
AQST Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.446 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -14.673 |
| Enterprise Value to Sales | 3.928 |
| Total Debt to Enterprise Value | 0.497 |
AQST Efficiency
| Revenue/Employee | 374,688.889 |
| Income Per Employee | -58,296.296 |
| Receivables Turnover | 5.971 |
| Total Asset Turnover | 0.884 |
AQST Liquidity
| Current Ratio | 2.238 |
| Quick Ratio | 1.868 |
| Cash Ratio | 1.304 |
AQST Profitability
| Gross Margin | 59.245 |
| Operating Margin | -29.429 |
| Pretax Margin | -15.074 |
| Net Margin | -15.559 |
| Return on Assets | -13.748 |
| Return on Equity | N/A |
| Return on Total Capital | 102.674 |
| Return on Invested Capital | N/A |
AQST Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -1,289.263 |
| Total Debt to Total Assets | 172.11 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -1,258.643 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Aquestive Therapeutics Inc. - AQST
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 45.85M | 50.83M | 47.68M | 50.58M | |
Sales Growth
| -12.85% | +10.87% | -6.20% | +6.09% | |
Cost of Goods Sold (COGS) incl D&A
| 12.96M | 14.99M | 19.88M | 20.61M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 3.61M | 2.96M | 2.39M | 1.34M | |
Depreciation
| 3.56M | 2.91M | 2.27M | 1.19M | |
Amortization of Intangibles
| 51.00K | 51.00K | 116.00K | 157.00K | |
COGS Growth
| -36.33% | +15.62% | +32.65% | +3.68% | |
Gross Income
| 32.88M | 35.84M | 27.80M | 29.97M | |
Gross Income Growth
| +1.98% | +8.99% | -22.45% | +7.81% | |
Gross Profit Margin
| +71.72% | +70.51% | +58.30% | +59.25% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 75.78M | 70.52M | 69.86M | 44.85M | |
Research & Development
| 19.89M | 17.05M | 17.31M | 13.10M | |
Other SG&A
| 55.89M | 53.48M | 52.55M | 31.75M | |
SGA Growth
| -10.76% | -6.94% | -0.93% | -35.80% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 13.82M | 1.60M | - |
EBIT after Unusual Expense
| (42.89M) | (48.50M) | (42.07M) | (16.48M) | |
Non Operating Income/Expense
| 132.00K | 423.00K | 99.00K | 16.32M | |
Non-Operating Interest Income
| - | - | 132.00K | 423.00K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 13.02M | 22.46M | 12.44M | 7.46M | |
Interest Expense Growth
| +39.75% | +72.49% | -44.60% | -40.03% | |
Gross Interest Expense
| 13.02M | 22.46M | 12.44M | 7.46M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (55.78M) | (70.54M) | (54.41M) | (7.63M) | |
Pretax Income Growth
| +15.79% | -26.45% | +22.87% | +85.99% | |
Pretax Margin
| -121.67% | -138.77% | -114.11% | -15.07% | |
Income Tax
| - | - | - | 245.00K | - |
Income Tax - Current - Domestic
| - | - | - | 245.00K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (55.78M) | (70.54M) | (54.41M) | (7.87M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (55.78M) | (70.54M) | (54.41M) | (7.87M) | |
Net Income Growth
| +15.79% | -26.45% | +22.87% | +85.54% | |
Net Margin Growth
| -121.67% | -138.77% | -114.11% | -15.56% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (55.78M) | (70.54M) | (54.41M) | (7.87M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (55.78M) | (70.54M) | (54.41M) | (7.87M) | |
EPS (Basic)
| -1.6577 | -1.8525 | -1.1165 | -0.1285 | |
EPS (Basic) Growth
| +36.55% | -11.75% | +39.73% | +88.49% | |
Basic Shares Outstanding
| 33.65M | 38.08M | 48.73M | 61.26M | |
EPS (Diluted)
| -1.6577 | -1.8525 | -1.1165 | -0.1285 | |
EPS (Diluted) Growth
| +36.55% | -11.75% | +39.73% | +88.49% | |
Diluted Shares Outstanding
| 33.65M | 38.08M | 48.73M | 61.26M | |
EBITDA
| (39.28M) | (31.71M) | (39.68M) | (13.54M) | |
EBITDA Growth
| +20.83% | +19.27% | -25.11% | +65.87% | |
EBITDA Margin
| -85.68% | -62.39% | -83.22% | -26.77% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 10.063 | |
| Number of Ratings | 9 | Current Quarters Estimate | -0.133 | |
| FY Report Date | 03 / 2025 | Current Year's Estimate | -0.572 | |
| Last Quarter’s Earnings | -0.13 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.437 | Next Fiscal Year Estimate | -0.452 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 6 | 6 | 9 | 5 |
| Mean Estimate | -0.13 | -0.14 | -0.57 | -0.45 |
| High Estimates | -0.12 | -0.12 | -0.43 | -0.25 |
| Low Estimate | -0.16 | -0.16 | -0.78 | -0.72 |
| Coefficient of Variance | -11.29 | -13.62 | -22.10 | -43.97 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 7 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Aquestive Therapeutics Inc. - AQST
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Aquestive Therapeutics Inc. - AQST
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Aug 13, 2024 | Carl N. Kraus Chief Medical Officer | 251,681 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $3.43 per share | 863,265.83 |
| Jun 11, 2024 | Sherry Korczynski SVP Sales and Marketing | 25,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 14, 2024 | Stephen Wargacki Chief Science Officer | 267,963 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 20, 2024 | A. Mark Schobel Chief Innovation/Tech Officer | 984,476 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6 per share | 5,906,856.00 |
| Mar 13, 2024 | A. Ernest Toth SVP, Chief Financial Officer | 248,295 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.88 per share | 1,211,679.60 |
| Mar 13, 2024 | Daniel Barber President and CEO | 845,364 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.88 per share | 4,125,376.32 |
| Mar 13, 2024 | Peter Boyd See Remark | 237,628 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.88 per share | 1,159,624.64 |
| Mar 13, 2024 | Lori J. Braender SVP, General Counsel | 313,231 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.88 per share | 1,528,567.28 |
| Mar 12, 2024 | A. Mark Schobel Chief Innovation/Tech Officer | 1,034,476 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.88 per share | 5,048,242.88 |
| Mar 12, 2024 | Stephen Wargacki SVP, Research & Development | 257,963 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.88 per share | 1,258,859.44 |
| Mar 12, 2024 | Cassie Jung SVP, Operations | 237,754 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.88 per share | 1,160,239.52 |
| Mar 12, 2024 | Cassie Jung SVP, Operations | 238,886 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.88 per share | 1,165,763.68 |
| Mar 11, 2024 | Stephen Wargacki SVP, Research & Development | 56,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Cassie Jung SVP, Operations | 50,625 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Lori J. Braender SVP, General Counsel | 67,500 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Peter Boyd See Remark | 43,125 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Daniel Barber President and CEO | 363,900 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | Carl N. Kraus Chief Medical Officer | 56,250 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 11, 2024 | A. Ernest Toth SVP, Chief Financial Officer | 60,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |